Theseus Pharmaceuticals (NASDAQ:THRX) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Theseus Pharmaceuticals (NASDAQ:THRXGet Rating) from a sell rating to a hold rating in a report published on Thursday, reports.

According to Zacks, “Theseus Pharmaceuticals Inc. is a biopharmaceutical company. It focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company’s principal product candidate includes THE-630. Theseus Pharmaceuticals Inc. is based in CAMBRIDGE, Mass. “

Separately, Cantor Fitzgerald reaffirmed an overweight rating on shares of Theseus Pharmaceuticals in a research report on Friday, April 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from, Theseus Pharmaceuticals currently has an average rating of Buy and a consensus target price of $22.40.

Shares of Theseus Pharmaceuticals stock opened at $7.16 on Thursday. Theseus Pharmaceuticals has a 52-week low of $6.73 and a 52-week high of $24.54. The stock has a 50-day simple moving average of $10.77 and a 200-day simple moving average of $11.61.

Theseus Pharmaceuticals (NASDAQ:THRXGet Rating) last posted its earnings results on Thursday, March 10th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). Equities analysts expect that Theseus Pharmaceuticals will post -1.26 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Boxer Capital LLC acquired a new position in Theseus Pharmaceuticals in the fourth quarter worth $11,311,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Theseus Pharmaceuticals during the fourth quarter valued at $9,657,000. Omega Fund Management LLC acquired a new position in shares of Theseus Pharmaceuticals during the fourth quarter valued at $9,022,000. Nextech Invest AG acquired a new position in shares of Theseus Pharmaceuticals during the fourth quarter valued at $7,751,000. Finally, BlackRock Inc. increased its holdings in Theseus Pharmaceuticals by 2.2% in the first quarter. BlackRock Inc. now owns 544,855 shares of the company’s stock valued at $6,282,000 after purchasing an additional 11,592 shares during the last quarter. 90.00% of the stock is currently owned by institutional investors.

About Theseus Pharmaceuticals (Get Rating)

Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial.

Read More

Get a free copy of the Zacks research report on Theseus Pharmaceuticals (THRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Theseus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theseus Pharmaceuticals and related companies with's FREE daily email newsletter.